Edition:
United Kingdom

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

85.66EUR
1:00pm BST
Change (% chg)

€-0.26 (-0.30%)
Prev Close
€85.92
Open
€86.20
Day's High
€86.46
Day's Low
€85.66
Volume
157,999
Avg. Vol
614,815
52-wk High
€93.82
52-wk Low
€76.42

Chart for

About

Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the... (more)

Overall

Beta: 0.37
Market Cap(Mil.): €25,665.52
Shares Outstanding(Mil.): 307.96
Dividend: 0.96
Yield (%): 1.15

Financials

  FMEG.DE Industry Sector
P/E (TTM): 20.57 28.42 32.76
EPS (TTM): 4.05 -- --
ROI: 8.40 6.87 14.61
ROE: 13.39 10.79 16.34

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

11 Jun 2018

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

11 Jun 2018

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT, June 11 Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

11 Jun 2018

BRIEF-Fresenius Medical Care CEO: Looking To Pick-Up M&A Pace

* CEO TELLS Q1 ANALYST CALL WE ARE LOOKING TO BE MORE ACTIVE IN THE ACQUISITION ARENA; IT'S SMALL THINGS Further company coverage: (Reporting By Berlin Newsroom)

03 May 2018

Deals of the day-Mergers and acquisitions

April 23 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

23 Apr 2018

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

23 Apr 2018

Fresenius pulls out of Akorn takeover over data integrity

BERLIN German healthcare group Fresenius SE said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drug maker.

22 Apr 2018

Fresenius Medical cuts 2018 sales target after drug dosage shift

BERLIN German dialysis specialist Fresenius Medical Care cut its 2018 sales target due to lower than expected doses of calcimimetic drugs at its dialysis service business in the United States.

22 Apr 2018

Fresenius Medical cuts 2018 sales target after drug dosage shift

BERLIN German dialysis specialist Fresenius Medical Care cut its 2018 sales target due to lower than expected doses of calcimimetic drugs at its dialysis service business in the United States.

22 Apr 2018

UPDATE 1-Fresenius Medical cuts 2018 sales target after drug dosage shift

* Now sees 2018 revenue growth of 5-7 pct at constant currency

22 Apr 2018

Earnings vs. Estimates